OMCL logo

Omnicell, Inc. Stock Price

NasdaqGS:OMCL Community·US$1.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

OMCL Share Price Performance

US$29.72
-13.01 (-30.45%)
46.0% undervalued intrinsic discount
US$55.00
Fair Value
US$29.72
-13.01 (-30.45%)
46.0% undervalued intrinsic discount
US$55.00
Fair Value
Price US$29.72
AnalystHighTarget US$55.00
AnalystConsensusTarget US$44.33
AnalystLowTarget US$34.00

OMCL Community Narratives

AnalystHighTarget·
Fair Value US$55 42.8% undervalued intrinsic discount

Aging Population And Digital Transformation Will Drive Medication Automation

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value US$44 28.5% undervalued intrinsic discount

OmniSphere Adoption Will Simplify Healthcare Medication Management

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystLowTarget·
Fair Value US$34 7.5% undervalued intrinsic discount

Government Cost Containment And Cybersecurity Burdens Will Impair Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent OMCL News & Updates

Omnicell (NASDAQ:OMCL) May Have Issues Allocating Its Capital

Jul 16
Omnicell (NASDAQ:OMCL) May Have Issues Allocating Its Capital

Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 27% Below Their Intrinsic Value Estimate

Jun 28
Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 27% Below Their Intrinsic Value Estimate

Omnicell, Inc. Key Details

US$1.1b

Revenue

US$645.1m

Cost of Revenue

US$504.5m

Gross Profit

US$481.4m

Other Expenses

US$23.1m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 30, 2025
Earnings per share (EPS)
0.50
Gross Margin
43.88%
Net Profit Margin
2.01%
Debt/Equity Ratio
27.0%

Omnicell, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet and slightly overvalued.

0 Risks
3 Rewards

About OMCL

Founded
1992
Employees
3650
CEO
Randall Lipps
WebsiteView website
www.omnicell.com

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital; and specialized automated dispensing systems for hospitals, health systems, and post-acute care facilities. It also provides central pharmacy dispensing services; IV compounding services; turnkey solution designed to help health systems establish, manage, and optimize an entity-owned specialty pharmacy, as well as support onsite management of specialty pharmacy services, including payer contracting, staffing, licensing, and 340B program administration. In addition, the company offers inventory optimization services comprising predictive and prescriptive analytics, benchmarking, workflow tools, and clinical resources, as well as medication inventory visibility; patient engagement, clinical, and financial solutions; medication adherence solutions, which include single-dose automation solutions, automated and semi-automated filling equipment, various medication blister card packaging and packaging supplies; and software that guides users through the manual filling process. Further, it provides professional services, such as technology installation, program management, customer education and training, change management services, and related offerings; technical services comprising post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; and retail pharmacy and hospital automation outside the United States business. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. The company was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.7%
  • 3 Months: 5.1%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.7%, driven by a pullback of 2.5% in the Information Technology sector. As for the longer term, the market has actually risen by 13% in the last year. Earnings are forecast to grow by 15% annually. Market details ›